Association of fasting glucagon and proinsulin concentrations with insulin resistance

Diabetologia

Volumn 50, Issue 11, 2007, Pages 2342-2347

  Ferrannini, E ^a   Muscelli, E ^a   Natali, A ^a   Gabriel, R ^b   Mitrakou, A ^c   Flyvbjerg, A ^d   Golay, A ^e   Hojlund, K ^f  

^a UNIVERSITY OF PISA   (Italy)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c UNIVERSITY OF ATHENS   (Greece)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adiponectin; Alpha cell dysfunction; Beta cell dysfunction; Glucagon; Insulin resistance; Proinsulin

Indexed keywords

C PEPTIDE; GLUCAGON; PROINSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MALE; MULTIVARIATE ANALYSIS; PROINSULIN;

EID: 34848862525     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0806-x     Document Type: Article

References (27)

1. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110
2. Aronoff SL, Bennett PH, Unger RH (1977) Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. J Clin Endocrinol Metab 44:968-972
3. Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29
4. Cherrington AD (1997) Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48:1198-1214
5. Ahrén B, Larsson H (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23:650-657
6. Ahrén B (2006) Glucagon secretion in relation to insulin sensitivity in healthy subjects. Diabetologia 49:117-122
7. Mako ME, Starr JI, Rubenstein AH (1977) Circulating proinsulin in patients with maturity onset diabetes. Am J Med 63:865-869
8. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355-360
9. Porte D Jr, Kahn SE (1989) Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta cell dysfunction? Diabetes 38:1333-1336
10. Pradhan AD, Manson JE, Meigs JB et al (2003) Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med 114:438-444
11. Hanley AJ, D'Agostino R Jr, Wagenknecht LE, Saad MF, Savage PJ, Bergman R, Haffner SM; Insulin Resistance Atherosclerosis Study (2002) Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes 51:1263-1270
12. Rhodes CJ, Alarcon C (1994) What beta cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin processing mechanism. Diabetes 43:511-517
13. Alarcon C, Leahy JL, Schuppin GT, Rhodes CJ (1995) Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. J Clin Invest 95:1032-1039
14. Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC study (The European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk): I. Methodology and objectives. Diabetologia 47:566-570
15. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A (2005) Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48:1911-1918
16. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2000) Diabetes Care 23(Suppl 1):S4-S19
17. Ferrannini E, Mari A (1998) How to measure insulin sensitivity. J Hypertens 16:895-906
18. Olsen HL, Theander S, Bokvist K, Buschard K, Wollheim CB, Gromada J (2005) Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146:4861-4870
19. Gromada J, Franklin I, Wollheim CB (2007) Alpha cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84-116
20. Groop LC, Ferrannini E (1993) Insulin action and substrate competition. Baillieres Clin Endocrinol Metab 7:1007-1032
21. Ferrannini E, DeFronzo RA, Sherwin RS (1982) Transient hepatic response to glucagon in man: role of insulin and hyperglycemia. Am J Physiol 242:E73-E81
22. Chen SS, Zhang Y, Santomango TS, Williams PE, Lacy DB, McGuinness OP (2007) Glucagon chronically impairs hepatic and muscle glucose uptake. Am J Physiol Endocrinol Metab 292:E928-E935
23. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR (1999) Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that of type 2 diabetes. Cell 96:329-339
24. Ueki K, Okada T, Hu J, Liew CW et al (2006) Total insulin and IGF-1 resistance in pancreatic β cells caused overt diabetes. Nat Gen 38:583-588
25. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G (1997) Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 100:1166-1173
26. Ferrannini E, Camastra S, Gastaldelli A et al (2004) Beta-cell function in obesity: effects of weight loss. Diabetes 53(Suppl 3):S26-S33
27. Rana JS, Li TY, Manson JE, Hu FB (2007) Adiposity compared with physical inactivity and risk of type 2 diabetes in women. Diabetes Care 30:53-58